Reduced expression of SFRP1 and SFRP5 caused by promoter hypermethylation has been documented in skin, oral submucosa, lung, kidney fibrosis, and SSc, while demethylating agents can partially reverse these fibrotic phenotypes. This evidence concerns the gene SFRP1 and systemic sclerosis.